Patients with sarcoidosis who fail to improve on corticosteroids pose a therapeutic challenge for clinicians, because there is a lack of consensus guidelines to manage these patients with other therapeutic options. Herein, we report one such patient with severe progressive sarcoidosis and review the alternative treatment options in patients with sarcoidosis who progress over corticosteroid therapy
Pulmonary hypertension can develop as a complication of sarcoidosis, even in the absence of parenchy...
Sarcoidosis is a systemic granulomatous inflammatory disease of unknown etiology. It affects the lun...
The Author(s) 2012. This article is published with open access at Springerlink.com Introduction: Sar...
Sarcoidosis is a granulomatous disease of unknown cause, occurs worldwide and has a highly variable ...
About half of patients with sarcoidosis will need systemic therapy for their disease. Oral glucocort...
There are no guidelines regarding the treatment of pulmonary sarcoidosis. Generally, oral corticoste...
Abstract Background Sarcoidosis is a multisystemic granulomatous disease of unknown origin. It is ch...
During the last two decades many advances have been made in the field of sarcoidosis. The disease is...
Sarcoidosis is a systemic disease of unknown cause with very diverse presentation, outcome, severity...
Corticosteroids are still the cornerstone of treatment for patients with sarcoidosis requiring syste...
Sarcoidosis is a systemic inflammatory disease of unknown etiology that is characterized by the pres...
Recent case reports and studies on treating COVID-19 in patients with chronic sarcoidosis describe d...
Sarcoidosis is a multisystem disorder of unknown cause with a highly variable course. Corticosteroid...
Background Pulmonary hypertension (PH) is one of the significant complications of sarcoidosis. In th...
SummaryThis manuscript offers an approach to the treatment of pulmonary sarcoidosis based on current...
Pulmonary hypertension can develop as a complication of sarcoidosis, even in the absence of parenchy...
Sarcoidosis is a systemic granulomatous inflammatory disease of unknown etiology. It affects the lun...
The Author(s) 2012. This article is published with open access at Springerlink.com Introduction: Sar...
Sarcoidosis is a granulomatous disease of unknown cause, occurs worldwide and has a highly variable ...
About half of patients with sarcoidosis will need systemic therapy for their disease. Oral glucocort...
There are no guidelines regarding the treatment of pulmonary sarcoidosis. Generally, oral corticoste...
Abstract Background Sarcoidosis is a multisystemic granulomatous disease of unknown origin. It is ch...
During the last two decades many advances have been made in the field of sarcoidosis. The disease is...
Sarcoidosis is a systemic disease of unknown cause with very diverse presentation, outcome, severity...
Corticosteroids are still the cornerstone of treatment for patients with sarcoidosis requiring syste...
Sarcoidosis is a systemic inflammatory disease of unknown etiology that is characterized by the pres...
Recent case reports and studies on treating COVID-19 in patients with chronic sarcoidosis describe d...
Sarcoidosis is a multisystem disorder of unknown cause with a highly variable course. Corticosteroid...
Background Pulmonary hypertension (PH) is one of the significant complications of sarcoidosis. In th...
SummaryThis manuscript offers an approach to the treatment of pulmonary sarcoidosis based on current...
Pulmonary hypertension can develop as a complication of sarcoidosis, even in the absence of parenchy...
Sarcoidosis is a systemic granulomatous inflammatory disease of unknown etiology. It affects the lun...
The Author(s) 2012. This article is published with open access at Springerlink.com Introduction: Sar...